All In Biotech

Drug Trial Radar · NCT05478174

Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery

Last checked: Nov 19, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Jul 26, 2022

Primary completion

Nov 7, 2023

Study completion Nov 14, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.

Conditions

  • General Anesthesia

Interventions

  • HSK3486Drug

    HSK3486 for induction of general anesthesia

  • PropofolDrug

    Propofol for induction of general anesthesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success Rate of General Anesthesia InductionTime frame: From the time of study drug administration to desired depth of anesthesia to MOAA/S≤1 ( up to 5 minutes)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Shoals Medical Trials, Inc.

    Sheffield, Alabama

  • Arizona Research Center

    Phoenix, Arizona

  • UC Davis Health

    Davis, California

  • Coastal Clinical Research Specialists

    Jacksonville, Florida

  • University of Miami Hospital

    Miami, Florida

  • Gulfcoast Research Institute, Llc

    Sarasota, Florida

  • Phoenix Clinical Research

    Tamarac, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • NextStage Clinical Research - Abay Neuroscience Center

    Wichita, Kansas

  • Chesapeake Research Group, Llc

    Pasadena, Maryland

  • Brigham & Women'S Hospital

    Boston, Massachusetts

  • Duke University Health

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Midwest Clinical Research Center

    Dayton, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • HD Research

    Bellaire, Texas

  • Hd Research Llc.

    Carrollton, Texas

  • The University of Texas - MD Anderson Cancer Center

    Houston, Texas

  • Urology San Antonio Research

    San Antonio, Texas

  • Endeavor Clinical Trials

    San Antonio, Texas

  • Jbr Clinical Research

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.